Anti-VEGF Molecules for the Management of Diabetic Macular Edema

E-ISSN： 1873-4286|21|32|4731-4737

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.32, 2015-10, pp. : 4731-4737

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration

Current Drug Targets, Vol. 12, Iss. 2, 2011-01 ,pp. : 173-181

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging pharmacotherapies for diabetic macular edema

By Furlani Bruno A Meyer Carsten H Rodrigues Eduardo B Maia Mauricio Farah Michel E Penha Fernando M Holz Frank G

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 4, 2007-11 ,pp. : 591-603

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib octasodium for the treatment of diabetic macular edema

By Schartman Jerome P Coney Joseph M Hornik Joan H Miller David G

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1317-1323

Informa Healthcare

Access to resources Recommend Favorite

Resistance to Anti-VEGF Agents

Current Pharmaceutical Design, Vol. 10, Iss. 1, 2004-01 ,pp. : 51-64

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview

By Semeraro Francesco Morescalchi Francesco Duse Sarah Gambicorti Elena Romano Mario R Costagliola Ciro

Expert Opinion on Drug Safety, Vol. 13, Iss. 6, 2014-06 ,pp. : 785-802

Informa Healthcare

Access to resources Recommend Favorite